Charities have reacted angrily to the decision by the National Institute for Health and Clinical Excellence not to recommend the use of two colon cancer drugs.

Charities have reacted angrily to the decision by the National Institute for Health and Clinical Excellence not to recommend the use of two colon cancer drugs.

The final appraisal determination for bevacizumab (brand name Avastin) and cetuximab (Erbitux) recommended against their use for advanced cancer on the grounds they are not cost-effective. NICE said that although Avastin showed 'increased benefit' over standard chemotherapy, with trials showing survival extending by an average of five months, it was not convinced the drug - at£17,000 per course - was cost effective.

Subject to an appeal being received, final guidance is expected in November.